Haapiainen R K, Permi E J, Rannikko S A, Voutilainen P E, Liewendahl K, Stenman U H, Alfthan O S
Second Department of Surgery, Helsinki University Central Hospital, Finland.
Br J Urol. 1990 Mar;65(3):264-7. doi: 10.1111/j.1464-410x.1990.tb14723.x.
Serum acid phosphatase activity (ACP), prostate specific phosphatase (PAP) and prostate specific antigen (PSA) were measured in 100 patients with prostatic cancer. The patients were divided into 4 groups: T1-2 MO, T3-4 MO and M1 patients with less than or equal to 10 or greater than 10 metastatic foci in bone scintigraphy. The mean serum ACP levels were almost identical in the T1-2 MO and T3-4 MO groups and there was no significant difference between the mean PAP values. Significantly higher PSA levels were observed in the MO patients in the extracapsular category compared with those in the intracapsular category. The mean serum levels of all 3 tumour markers were significantly higher in the M1 than in the MO category. PSA seems to be the marker of choice as a diagnostic aid for differentiating between patients with intracapsular and those with extracapsular tumour growth. In prostatic cancer patients with bone metastases these markers were of similar value for staging the disease.
对100例前列腺癌患者测定了血清酸性磷酸酶活性(ACP)、前列腺特异性磷酸酶(PAP)和前列腺特异性抗原(PSA)。患者被分为4组:T1 - 2 MO、T3 - 4 MO以及骨闪烁显像中转移灶小于或等于10个或大于10个的M1患者。T1 - 2 MO组和T3 - 4 MO组的血清ACP平均水平几乎相同,PAP平均值之间无显著差异。与包膜内类型的MO患者相比,包膜外类型的MO患者PSA水平显著更高。M1组所有3种肿瘤标志物的血清平均水平均显著高于MO组。PSA似乎是区分包膜内肿瘤生长患者和包膜外肿瘤生长患者的诊断辅助首选标志物。在有骨转移的前列腺癌患者中,这些标志物在疾病分期方面具有相似的价值。